Good Progress But Challenges Remain For Japan’s AMED
This article was originally published in PharmAsia News
Executive Summary
Japan's year-old AMED is "now looking at how to expand its budget" and seeking new routes of cooperation, as it aims to foster better coordinated basic medical research between industry, academia and public institutes in the country.
You may also be interested in...
Japan Builds Asia Links Through New AMED Programs
In line with similar initiatives by Japan on other regulatory fronts, the country's Agency for Medical Research and Development is building up its partnerships and presence in Asia.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.